



PRESS RELEASE, JANUARY 27, 2015

## Moberg Pharma's fungal nail product approved in China

**Moberg Pharma AB (OMX: MOB) today announced that its partner, Menarini Asia-Pacific, has received approval for Moberg's fungal nail product in China. Launch preparations in several markets are progressing ahead of plan.**

Moberg Pharma's distribution agreement with the Menarini Group – a top 40 global pharmaceutical company - includes Italy, China and eight countries in Southeast Asia. Menarini has in addition initiated launch activities in Malaysia, Singapore and Hong Kong and preparations are ongoing in the other markets in the region.

*"We are excited about the progress that Menarini Asia-Pacific has made in registration and launch preparation activities. Kerasal Nail® has significant potential in the region. Assuming successful launches, the region will be an important contributor to revenues and earnings from 2015 and onwards," said Peter Wolpert, CEO of Moberg Pharma AB.*

### **For additional information contact:**

Peter Wolpert, CEO

Telephone: +46 (0)70 - 735 71 35

E-mail: [peter.wolpert@mobergpharma.se](mailto:peter.wolpert@mobergpharma.se)

Anna Ljung, CFO

Mobil: +46 (0)70- 766 60 30

Email: [anna.ljung@mobergpharma.se](mailto:anna.ljung@mobergpharma.se)

### **About this information**

Moberg Pharma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08:30 am (CET) on January 27, 2015.

### **About Moberg Pharma**

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with a direct sales and marketing organization in the U.S. and an extensive distributor network in more than 40 countries. The company's OTC portfolio includes the brands Kerasal®, Jointflex®, Kerasal Nail®, Domeboro®, Vanquish®, and Fergon®. Kerasal Nail® (Emtrix® and Nalox™ in certain markets outside the U.S.) is the leading product for the treatment of nail disorders in the U.S. and Nordic market. The current portfolio will be supplemented by the acquisition and in-licensing of additional products as well as product development with a focus on innovative drug delivery of proven compounds. Moberg Pharma has offices in Stockholm and New Jersey and the company's shares (OMX: MOB) are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: [www.mobergpharma.com](http://www.mobergpharma.com).